Physician profile
James Chou
NPI 1023177623
$974.68
in general payments reported to CMS, 2019-2025
12 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.62 · 2020: $21.72 · 2021: $239 · 2022: $53.37 · 2024: $310 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544 · Education: $65.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.41 |
| Education | $65.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $325.50 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $198.58 | 2021 | |
| Ferring Pharmaceuticals INC. | $140.98 | 2024 | Rebyota |
| Celltrion USA INC. | $65.63 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $64.79 | 2025 | Rezdiffra |
| Conmed Corporation | $53.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.95 | 2019 | |
| Medtronic Vascular, INC. | $23.67 | 2019 | |
| Intercept Pharmaceuticals, INC. | $21.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.25 | 2021 | |
| Daiichi Sankyo INC. | $19.10 | 2021 | |
| Braintree Laboratories, INC. | $13.14 | 2024 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.